Abstract
Immune protection is based on long-lived memory cells and effector cells, which are either cytotoxic or secrete antibodies. The lifespan of these effector cells has not so far been determined. Here we show that antibody-secreting plasma cells from bone marrow are as long-lived as memory B cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vieira, P. & Rajewsky, K. Eur. J. Immunol. 18, 313–316 (1988).
Slifka, M. K., Matloubian, M. & Ahmed, R. J. Virol. 69, 1895–1902 (1995).
MacLennan, I. C. M., Liu, Y. J. & Johnson, G. D. Immunol. Rev. 126, 143–161 (1992).
Ho, F., Lortan, J. E., MacLennan, I. C. M. & Khan, M. Eur. J. Immunol. 16, 1297–1301 (1986).
Smith, K. G., Hewitson, T. D., Nossal, G. J. & Tarlington, D. M. Eur. J. Immunol. 26, 444–448 (1996).
Manz, R. A., Assenmacher, M., Pflüger, E., Miltenyi, S. & Radbruch, A. Proc. Natl Acad. Sci. USA 92, 1921–1995 (1995).
Benner, R., Hijmans, W. & Haaijman, J. J. Clin. Exp. Immunol. 46, 1–6 (1981).
Schittek, B. & Rajewsky, K. Nature 346, 749–751 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manz, R., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133–134 (1997). https://doi.org/10.1038/40540
Issue Date:
DOI: https://doi.org/10.1038/40540
This article is cited by
-
Cell-based passive immunization for protection against SARS-CoV-2 infection
Stem Cell Research & Therapy (2023)
-
Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation (2022)
-
3-dose of RBD vaccine is sufficient to elicit a long-lasting memory response against SARS-CoV-2 infection
Signal Transduction and Targeted Therapy (2022)
-
B-Lymphozyten und Plasmazellen als Treiber rheumatischer Erkrankungen
Zeitschrift für Rheumatologie (2022)
-
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice
npj Vaccines (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.